Intercept Pharmaceuticals, Inc.
16 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
8
Ending by 2030
Aug 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 6, 2027The maintenance fee for Methods of treating cancer (US 10,369,160) comes due Feb 6, 2027. Unpaid by Aug 6, 2027, it lapses early.
- 1 fee due May 7, 2027The maintenance fee for TGR5 Modulators and Methods of Use Thereof (US 11,807,659) comes due May 7, 2027. Unpaid by Nov 8, 2027, it lapses early.
- 2 fees due Aug 4, 2027
- 1 fee due Sep 30, 2027The maintenance fee for Methods for preparation of bile acids and derivatives thereof (US 10,604,544) comes due Sep 30, 2027. Unpaid by Mar 31, 2028, it lapses early.
- 1 fee due Nov 12, 2027The maintenance fee for Compositions of Obeticholic Acid and Methods of Use (US 10,646,499) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,546,365 | Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions In force · From the USPTO record | In force | From the USPTO record | |
| US 7,994,352 | Process for preparing 3a(β)-7a(β)-dihydroxy-6a(β)-alkyl-5β-cholanic acid In force · From the USPTO record | In force | From the USPTO record | |
| US 7,932,244 | Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions In force · From the USPTO record | In force | From the USPTO record | |
| US 9,540,414 | TGR5 modulators and methods of use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 8,114,862 | TGR5 modulators and methods of use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 8,410,083 | 23-substituted bile acids as TGR5 modulators and methods of use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 8,796,249 | TGR5 modulators and methods of use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 8,999,964 | TGR5 modulators and methods of use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,777,038 | Process for preparing bile acid derivatives In force · From the USPTO record | In force | From the USPTO record | |
| US 10,894,054 | FXR agonist compositions for combination therapy In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 27: 16 patents in force now held by others · 11 lapsed for an unpaid fee · 8 ended at full term · 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
7 pending · 13 abandoned · 23 no status recorded